Effect of probiotics (<i>Lactobacillus plantarum</i> 299 plus Bifidobacterium Cure21) in patients with poor ileal pouch function: a randomised controlled trial

Bengtsson, Johanna; Adlerberth, Ingegerd; Östblom, Anna; Saksena, Pushpa; Øresland, Tom; Börjesson, Lars

doi:10.3109/00365521.2016.1161067

Cited by 24 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microbial analysis revealed that the probiotic enriched lactobacilli and bifidobacteria and increased bacteria diversity while reducing fungal diversity [126]. In contrast, probiotics containing Lactobacillus and Bifidobacterium did not improve pouch dysfunction nor pouchitis activity [127].…”

Section: Pouchitismentioning

confidence: 99%

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

2020

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), including Crohn's disease, ulcerative colitis, and pouchitis, are chronic, relapsing intestinal inflammatory disorders mediated by dysregulated immune responses to resident microbiota. Current standard therapies that block immune activation with oral immunosuppressives or biologic agents are generally effective, but each therapy induces a sustained remission in only a minority of patients. Furthermore, these approaches can have severe adverse events. Recent compelling evidence of a role of unbalanced microbiota (dysbiosis) driving immune dysfunction and inflammation in IBD supports the therapeutic rationale for manipulating the dysbiotic microbiota. Traditional approaches using currently available antibiotics, probiotics, prebiotics, and synbiotics have not produced optimal results, but promising outcomes with fecal microbiota transplant provide a proof of principle for targeting the resident microbiota. Rationally designed oral biotherapeutic products (LBPs) composed of mixtures of protective commensal bacterial strains demonstrate impressive preclinical results. Resident microbial-based and microbialtargeted therapies are currently being studied with increasing intensity for IBD primary therapy with favorable early results. This review presents current evidence and therapeutic mechanisms of microbiota modulation, emphasizing clinical studies, and outlines prospects for future IBD treatment using new approaches, such as LBPs, bacteriophages, bacterial function-editing substrates, and engineered bacteria. We believe that the optimal clinical use of microbial manipulation may be as adjuvants to immunosuppressive for accelerated and improved induction of deep remission and as potential safer solo approaches to sustained remission using personalized regimens based on an individual patient's microbial profile.

show abstract

Section: Pouchitismentioning

confidence: 99%

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

2020

View full text Add to dashboard Cite

show abstract

“…However, when exploring individual studies, it has been demonstrated that 6 g/day of a multistrain probiotic containing a combination of lactic acid bacteria, streptococci and bifidobacteria can help maintain remission [ 80 ] and prevent acute pouchitis [ 81 , 82 ]. There is a single small trial suggestive that probiotics may be effective for acute pouchitis [ 83 ] but this was not replicated in a RCT [ 84 ] and hence its position in acute pouchitis remains uncertain.…”

Section: Therapies Involving Microbial Manipulation In Pouchitismentioning

confidence: 99%

The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis

et al. 2021

View full text Add to dashboard Cite

The gut microbiome has been implicated in a range of diseases and there is a rapidly growing understanding of this ecosystem’s importance in inflammatory bowel disease. We are yet to identify a single microbe that causes either ulcerative colitis (UC) or pouchitis, however, reduced microbiome diversity is increasingly recognised in active UC. Manipulating the gut microbiome through dietary interventions, prebiotic and probiotic compounds and faecal microbiota transplantation may expand the therapeutic landscape in UC. Specific diets, such as the Mediterranean diet or diet rich in omega-3 fatty acids, may reduce intestinal inflammation or potentially reduce the risk of incident UC. This review summarises our knowledge of gut microbiome therapies in UC and pouchitis.

show abstract

“…However, when exploring individual studies, it has been demonstrated that 6 g/day of a multistrain probiotic containing a combination of lactic acid bacteria, streptococci and bifidobacteria can help maintain remission 55 and prevent acute pouchitis 56,57 . There is a single small trial suggestive that probiotics may be effective for acute pouchitis 58 but this was not replicated in a randomised controlled trial 59 and hence its position in acute pouchitis remains uncertain.…”

Section: Probiotic Studies In Pouchitismentioning

confidence: 99%

The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis

Segal¹,

LeBlanc²,

Braz³

et al. 2021

Preprint

View full text Add to dashboard Cite

The gut microbiome is important in the homeostasis of gut health and has pivotal roles in digestion, immune regulation, and metabolic processes. The gut microbiome has been implicated in range of diseases and there is a rapidly growing understanding of this ecosystem’s importance in inflammatory bowel disease. We have yet to identify a single microbe that causes either ulcerative colitis or pouchitis, however, perturbations in the gut microbiome are associated with disease states. Importantly, we can manipulate the gut microbiome using dietary interventions, medications, and faecal microbiota transplantation. This review will summarise our knowledge of gut microbiome therapies in ulcerative colitis and pouchitis.

show abstract

Effect of probiotics (Lactobacillus plantarum 299 plus Bifidobacterium Cure21) in patients with poor ileal pouch function: a randomised controlled trial

Abstract: The hypothesis that probiotics improves pouch-related dysfunction was not confirmed. Faecal biomarkers could play a future role in the management of pouch patients.

Cited by 24 publications

References 27 publications

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases

The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis

The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis

Contact Info

Product

Resources

About